Last updated: 11/07/2018 19:24:34
A phase III, multicentre, randomised, double-blind, parallel group study assessing the efficacy and safety of inhaled salmeterol xinafoate 100?g bd via the Diskhaler versus inhaled salbutamol 400?g qds via the Diskhaler in the treatment of patients with moderate to severe asthma.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A phase III, multicentre, randomised, double-blind, parallel group study assessing the efficacy and safety of inhaled salmeterol xinafoate 100?g bd via the Diskhaler versus inhaled salbutamol 400?g qds via the Diskhaler in the treatment of patients with moderate to severe asthma.
Trial description: A phase III, multicentre, randomised, double-blind, parallel group study assessing the efficacy and safety of inhaled salmeterol xinafoate 100?g bd via the Diskhaler versus inhaled salbutamol 400?g qds via the Diskhaler in the treatment of patients with moderate to severe asthma.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Faurschou P, Steffensen I. Jacques L et al. Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. Eur Respir J 1996; 9: 1885-1890.
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1992-10-09
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website